

## PATENT

Docket No. GC527C3

SN 09/768,080

☐ Urgent  
☐ Confidential  
☐ Action Required  
☐ Reply Requested  
☐ For Your Info.

**FAX COVER SHEET****TO:** Art Unit 1644**LOCATION:** USPTO**Fax No.:** (703) 872-9306, (Before Final Facsimile No.)**FROM:** Carol See for Kamrin T. MacKnight

**LOCATION:** GENENCOR INTERNATIONAL, INC.  
Legal Department  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-7549  
Fax: 650-845-6504

FAX RECEIVED

APR 8 2003

GROUP 1600

**DATE:** April 7, 2003**NUMBER OF PAGES TO FOLLOW: 13 SENT BY: cas**

Re: Serial No. 09/768,080, Attorney Docket No. GC527C3

Attachments: Transmittal Letter (1 page) in duplicate, and Response to Office Action (11 pages).

The original of this facsimile will be sent to you via:

☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent

☒ Please initial acknowledgment of receipt by return facsimile \_\_\_\_\_

NOTE: The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (650/846-7517) and return the original transmission to us by mail.

GC527C3 faxcvf-ptb

Received from &lt;650 845 6504&gt; at 4/7/03 2:22:06 PM [Eastern Daylight Time]

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Before Final Facsimile No. (703) 872-9306, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: April 7, 2003

By:

  
Carol A. See

**PATENT**  
**Docket No. GC527C3**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
David A. Estell et al.	)	Group Art Unit: 1644
Serial No.: 09/768,080	)	Examiner: Saunders, David A.
Filed: January 23, 2001	)	
For: Proteins Producing an Altered	)	
Immunogenic Response and	)	
Methods of Making and Using	)	
the Same	)	

**TRANSMITTAL LETTER**

Commissioner for Patents  
Washington, D.C. 20231


Sir:

In response to the Office Action dated January 7, 2003, enclosed please find the following document: Response to Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527-C3). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: April 7, 2003

  
Kamrin T. MacKnight  
Registration No. 38,230

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-5838  
Fax: 650-845-6504

GC527-C3

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Before Final Facsimile No. (703) 872-9306, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: April 7, 2003

By: Carol A. See

Carol A. See

PATENT  
Docket No. GC527C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	
	)	
Estell et al.	)	Group Art Unit: 1644
	)	
Serial No.: 09/768,080	)	Examiner: Saunders, D.
	)	
Filed: January 23, 2001	)	
	)	
For: Proteins Producing an Altered	)	
Immunogenic Response and	)	
Methods of Making and Using	)	
the Same	)	

RESPONSE TO OFFICE ACTION MAILED JANUARY 7, 2003

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action mailed January 14 2003, Applicants respectfully request that the following amendments be made.

Instructions to amend the specification, and replacement or added paragraphs in clean form pursuant to 37 C.F.R. §1.121(b), and a clean version of the rewritten, added, and/or cancelled claims with instructions for entry pursuant to 37 C.F.R. §1.121 (c)(1)(i) is included beginning on page 2 of this communication. A marked-up version of the specification's replacement paragraphs pursuant to 37 C.F.R. §1.121(b), as well as rewritten, added, and/or cancelled claims pursuant to 37 C.F.R. §1.121 (c)(1)(ii) is attached as Appendix I. A clean version of the entire set of pending claims pursuant to 37 C.F.R. §1.121 (c)(3) as they would appear following entry of this amendment is attached as Appendix II.

GC527C3 Response to Office Action